Press Releases Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-05-19 pm EDT			5-day change	1st Jan Change
5.990 ^USD	-1.48%		-6.70%	-32.09%

May. 07	Vanda Pharmaceuticals Inc., Q1 2026 Earnings Call, May 06, 2026
May. 06	Vanda Pharmaceuticals Inc. Raises Revenue Guidance for the Full-Year 2026	CI

Press Releases

May. 07	Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences	PR
May. 06	Vanda: Q1 Earnings Snapshot	AQ
May. 06	Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results	PR
May. 04	Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years	PR
May. 01	Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years	PR
Apr. 29	Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026	PR
Apr. 28	Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence	PR
Apr. 22	Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors	PR
Apr. 09	Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines	PR
Apr. 08	Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists	PR
Mar. 19	Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods	PR
Mar. 03	Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years	PR
Feb. 26	Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference	PR
Feb. 25	Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis	PR
Feb. 20	Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation	PR
Feb. 11	Vanda: Q4 Earnings Snapshot	AQ
Feb. 11	Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results	PR
Feb. 04	Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026	PR
Jan. 08	Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder	PR
Dec. 30	Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness	PR
Dec. 11	Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference	PR
Dec. 04	Vanda Pharmaceuticals : FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness	PU
Dec. 04	FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness	PR
Nov. 28	Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness	PR
Nov. 17	Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting	PR